KeyCorp Cuts Certara (NASDAQ:CERT) Price Target to $12.00

Certara (NASDAQ:CERT) had its price target cut by KeyCorp from $13.00 to $12.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the stock. KeyCorp’s price objective points to a potential upside of 26.34% from the company’s current price.

Several other research analysts have also recently issued reports on the company. Morgan Stanley reduced their price objective on Certara from $16.00 to $12.00 and set an “equal weight” rating for the company in a research note on Thursday, December 18th. Redburn Partners set a $10.00 price target on shares of Certara in a report on Friday, November 21st. Rothschild Redb upgraded shares of Certara to a “strong-buy” rating in a research note on Friday, November 21st. Barclays dropped their price objective on shares of Certara from $14.00 to $13.00 and set an “overweight” rating on the stock in a report on Monday, December 15th. Finally, Stephens reduced their target price on shares of Certara from $15.00 to $12.00 and set an “overweight” rating for the company in a report on Friday, December 12th. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.58.

Certara Price Performance

CERT stock opened at $9.50 on Thursday. The company has a 50-day moving average price of $9.19 and a 200 day moving average price of $10.57. The stock has a market cap of $1.51 billion, a PE ratio of 135.57 and a beta of 1.46. Certara has a 12 month low of $8.02 and a 12 month high of $15.69. The company has a current ratio of 2.09, a quick ratio of 2.09 and a debt-to-equity ratio of 0.27.

Certara (NASDAQ:CERT) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.03. The firm had revenue of $104.62 million for the quarter, compared to analyst estimates of $104.53 million. Certara had a net margin of 2.62% and a return on equity of 5.18%. During the same period in the previous year, the company earned $0.13 earnings per share. Certara has set its FY 2025 guidance at 0.450-0.470 EPS. Equities research analysts anticipate that Certara will post 0.28 earnings per share for the current year.

Hedge Funds Weigh In On Certara

Large investors have recently bought and sold shares of the business. AdvisorNet Financial Inc acquired a new stake in Certara in the second quarter valued at approximately $25,000. First Horizon Corp purchased a new stake in shares of Certara during the third quarter worth about $30,000. Versant Capital Management Inc raised its position in shares of Certara by 66.7% during the 3rd quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock worth $35,000 after purchasing an additional 1,153 shares during the last quarter. Osaic Holdings Inc. lifted its stake in Certara by 50.7% in the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after buying an additional 1,175 shares in the last quarter. Finally, Elevation Point Wealth Partners LLC acquired a new stake in Certara in the 2nd quarter worth about $59,000. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.